Antibody-drug conjugate development has seen real progression over the last year within Asia. From our research with Miracogen, Remegen and MedImmune we can expect to see real advances in 2019. Now in its second year, World ADC Asia (June 11-13, Shanghai, China) is back following its initial success to overcome the challenges ADC drug developers are facing.
Across 3 days, with 120+ ADC experts, this comprehensive antibody-drug conjugates conference will enable you to propel your ADC pipeline into clinical development. You’ll explore lessons learned from working with regulatory bodies, reviewing latest phase I clinical readouts and confidently optimize ADC CMC processes to improve your manufacturing programs. Not only will World ADC Asia delve into general antibody-drug conjugate challenges is will also focus on challenges and opportunities specific to development within Asia.
Attend World ADC Asia to network with potential collaborators, foster new connections and further cement existing partnerships. This is the only ADC focused conference that will bring together all the key players within antibody-drug conjugates in Asia.
参与World ADC Asia 会议,与潜在合作伙伴建立联系,不仅意味着与新伙伴建立联系并且将进一步巩固现有合作关系。World ADC Asia 会议是唯一一个聚焦ADC的会议,将汇集亚洲范围内所有活跃在抗体药物偶联物领域的重要人物。
Download the Full Agenda on website (click contact us)
下载会议议程全文(点击联系我们)
Join expert speakers from large pharma, biotech companies, research institutions, regulatory bodies and technology experts who are accelerating the discovery and treatment of antibody-drug conjugates.